<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00313157</url>
  </required_header>
  <id_info>
    <org_study_id>2005-004221-26</org_study_id>
    <nct_id>NCT00313157</nct_id>
  </id_info>
  <brief_title>RATe Control in Atrial Fibrillation</brief_title>
  <acronym>RATAF</acronym>
  <official_title>Rate Control in Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asker &amp; Baerum Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asker &amp; Baerum Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of metoprolol, verapamil, diltiazem and
      carvedilol on ventricular rate, working capacity and quality of life in patients with chronic
      atrial fibrillation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomised, single blinded, cross-over study comparing the efficacy of metoprolol
      100 mg o.d., verapamil 240 mg o.d., diltiazem 360 mg o.d. and carvedilol 25 mg o.d. in
      reducing ventricular rate in atrial fibrillation. A total of 60 patients will be included,
      with a minimum of 20 women.Patients will receive each of the drug regimens in a random
      sequence. Each regimen will be administered for 3 weeks, ensuring that steady-state drug
      concentration will be attained and to provide an adequate washout of the previous treatment.
      Following each regimen, exercise ECG and Holter registration will be performed and patients
      will undergo laboratory evaluation and complete QoL-forms. They will then be started on the
      next randomly assigned treatment regimen, until the entire sequence of treatment schedules is
      completed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventricular rate</measure>
    <time_frame>Three weeks</time_frame>
    <description>Ventricular rate evaluated after three weeks on study drug treatment</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Metoprolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with Metoprolol 100 mg x 1 for three weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diltiazem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with Diltiazem 360 mg x 1 for three weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Verapamil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with Verapamil 240 mg x 1 for three weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carvedilol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with Carvedilol 25 mg x 1 for three weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol</intervention_name>
    <arm_group_label>Metoprolol</arm_group_label>
    <other_name>Selo-Zok</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diltiazem</intervention_name>
    <arm_group_label>Diltiazem</arm_group_label>
    <other_name>Cardizem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verapamil</intervention_name>
    <arm_group_label>Verapamil</arm_group_label>
    <other_name>Isoptin Retard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
    <arm_group_label>Carvedilol</arm_group_label>
    <other_name>Kredex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persistent or permanent atrial fibrillation with ventricular rate &gt; 80/min at rest
             and/or &gt; 100/min average at daytime.

          -  Male or female, age &gt; 18.

        Exclusion Criteria:

          -  Hypersensitivity or contraindication to metoprolol, verapamil, diltiazem or
             carvedilol.

          -  Coronary heart disease or heart failure

          -  Systolic blood pressure &lt; 100 mmHg

          -  AV-conduction disturbance

          -  Severe hepatic or renal dysfunction

          -  Thyrotoxicosis

          -  Ongoing treatment with Digitalis

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara Reinvik Fagertun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asker and Baerum Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vestre Viken Hospital Trust, Baerum Hospital</name>
      <address>
        <city>Rud</city>
        <state>Akershus</state>
        <zip>1309</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2006</study_first_submitted>
  <study_first_submitted_qc>April 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2006</study_first_posted>
  <last_update_submitted>May 11, 2014</last_update_submitted>
  <last_update_submitted_qc>May 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asker &amp; Baerum Hospital</investigator_affiliation>
    <investigator_full_name>Sara Reinvik Ulimoe</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Verapamil</mesh_term>
    <mesh_term>Carvedilol</mesh_term>
    <mesh_term>Diltiazem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

